Literature DB >> 9565850

The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.

A Simon1, A Revel, A Hurwitz, N Laufer.   

Abstract

PURPOSE: Our purpose was to review the available literature concerning the pathogenesis of ovarian hyperstimulation syndrome and, in light of the most recent information, to attempt to provide further insight on this iatrogenic complication associated with the induction of ovulation.
METHODS: Published studies related to this topic were identified through a computerized bibliographic search.
CONCLUSIONS: The exact mechanism for the development of ovarian hyperstimulation syndrome is still obscure. It is well established that the syndrome is associated with the process of ovulation induced by either luteinizing hormone or human chorionic gonadotropin. Following ovulation, one or more substances produced by the ovary are liberated in excess, increasing capillary permeability, resulting in the clinical features of the syndrome. It may well be that the syndrome is not triggered by a single mechanism but by the production and secretion of several substances acting in concert. These may include prostaglandins, cytokines, the ovarian reninangiotensin system, vascular endothelial growth factor, and nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565850      PMCID: PMC3454931          DOI: 10.1023/a:1023052419627

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  66 in total

1.  Potential leukocyte attractants in the bovine peri-ovulatory ovary.

Authors:  A V Sirotkin; M R Luck
Journal:  Reprod Nutr Dev       Date:  1995

2.  Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome.

Authors:  R S Morris; I L Wong; E Kirkman; E Gentschein; R J Paulson
Journal:  Hum Reprod       Date:  1995-06       Impact factor: 6.918

3.  Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome.

Authors:  M A Friedlander; J R Loret de Mola; J M Goldfarb
Journal:  Fertil Steril       Date:  1993-11       Impact factor: 7.329

4.  Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management.

Authors:  A Delbaere; P J Bergmann; C Gervy-Decoster; M Staroukine; Y Englert
Journal:  Fertil Steril       Date:  1994-10       Impact factor: 7.329

5.  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.

Authors:  N McClure; D L Healy; P A Rogers; J Sullivan; L Beaton; R V Haning; D T Connolly; D M Robertson
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

6.  Urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment.

Authors:  D Robertson; K Selleck; A M Suikkari; V Hurley; J Moohan; D Healy
Journal:  Hum Reprod       Date:  1995-09       Impact factor: 6.918

7.  Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.

Authors:  J Neulen; Z Yan; S Raczek; K Weindel; C Keck; H A Weich; D Marmé; M Breckwoldt
Journal:  J Clin Endocrinol Metab       Date:  1995-06       Impact factor: 5.958

8.  The involvement of nitric oxide in the ovulatory process in the rat.

Authors:  L Shukovski; A Tsafriri
Journal:  Endocrinology       Date:  1994-11       Impact factor: 4.736

9.  Interleukin-1 beta stimulates nitrite production in the rat ovary: evidence for heterologous cell-cell interaction and for insulin-mediated regulation of the inducible isoform of nitric oxide synthase.

Authors:  I Ben-Shlomo; E Kokia; M J Jackson; E Y Adashi; D W Payne
Journal:  Biol Reprod       Date:  1994-08       Impact factor: 4.285

10.  Nitric oxide: an autocrine regulator of human granulosa-luteal cell steroidogenesis.

Authors:  B J Van Voorhis; M S Dunn; G D Snyder; C P Weiner
Journal:  Endocrinology       Date:  1994-11       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.